A phase III investigator initiated trial of RS5614 for treatment of chronic myeloid leukaemia
Latest Information Update: 22 Feb 2024
Price :
$35 *
At a glance
- Drugs RS 5614 (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 22 Feb 2024 According to a Renascience media release, this trial is ongoing at the Tohoku University, Tokai university and Akita university.
- 22 Feb 2024 New trial record